Genentech to manage Phase Ib/II combining Tecentriq with Seattle Genetics' SGN-LIV1A

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) will manage a Phase Ib/II trial evaluating PD-L1 inhibitor Tecentriq atezolizumab in combination with SGN-LIV1A from Seattle Genetics Inc. (NASDAQ:SGEN) to treat second-line metastatic triple-negative breast cancer (TNBC). The trial will enroll up to 45 patients who have not been previously treated with immunotherapy. ...